Episodes 121-135 of 256
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
MinuteCE®Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
MinuteCE®Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
MinuteCE®Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
MinuteCE®Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
CME/CERedefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
- advertisement
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
CME/CEEmpowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
CME/CEBringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
CME/CEChairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
MinuteCE®Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
- advertisement
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
MinuteCE®Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
Interprofessional Coordination of Adverse Event Management
MinuteCE®Interprofessional Coordination of Adverse Event Management
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
MinuteCE®Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
